ArticleInsights into imaging2023
Dual-layer spectral-detector CT for predicting microsatellite instability status and prognosis in locally advanced gastric cancer.
Article in Insights into imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Whole-volume histogram analysis of spectral-computed tomography iodine maps characterizes HER2 expression in gastric cancer.World journal of gastroenterology · 2024Trial
- Can Spectral CT Complement Biopsy for MSI/dMMR Assessment in Esophagogastric Junction Adenocarcinoma?Radiology. Imaging cancer · 2026Article
- Dual-layer spectral detector computed tomography of peritumoral fat for preoperative prediction of tumor budding in colorectal adenocarcinoma.Diagnostic and interventional radiology (Ankara, Turkey) · 2026Article
- Spectral CT-based habitat analysis for predicting pathologic response to neoadjuvant therapy in gastric cancer.European radiology · 2026Article
- The added value of intratumoral and peritumoral radiomic scores based on iodine density map for preoperative prediction of lymphovascular invasion in patients with gastric adenocarcinoma: a two-center study.Abdominal radiology (New York) · 2026Article
- Research progress of the clinical application of dual-layer spectral computed tomography in gastrointestinal malignancies.World journal of radiology · 2026Review
- Noninvasive evaluation of treatment-related protein expression status in advanced gastric cancer using dynamic nomograms with dual-energy CT: a multicenter study.European radiology · 2026Article
- Article
- The clinical applications of dual-layer spectral detector CT in digestive system diseases.European radiology · 2025Review
- Diagnostic value of dual-layer spectral detector CT parameters for differentiating high- from low-grade bladder cancer.Insights into imaging · 2025Article
- Radiomics analysis of dual-layer spectral-detector CT-derived iodine maps for predicting tumor deposits in colorectal cancer.European radiology · 2025Article
- A quantitative model using multi-parameters in dual-energy CT to preoperatively predict serosal invasion in locally advanced gastric cancer.Insights into imaging · 2024Article
- Assessing muscle invasion in bladder cancer via virtual biopsy: a study on quantitative parameters and classical radiomics features from dual-energy CT imaging.BMC medical imaging · 2024Article
- Differentiating between benign and malignant breast lesions using dual-energy CT-based model: development and validation.Insights into imaging · 2024Article
- Nomogram based on dual-energy CT-derived extracellular volume fraction for the prediction of microsatellite instability status in gastric cancer.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo construct and validate a prediction model based on dual-layer detector spectral CT (DLCT) and clinico-radiologic features to predict the microsatellite instability (MSI) status of gastric cancer (GC) and to explore the relationship between the prediction results and patient prognosis.
methodsA total of 264 GC patients who underwent preoperative DLCT examination were randomly allocated into the training set (n = 187) and validation set (n = 80). Clinico-radiologic features and DLCT parameters were used to build the clinical and DLCT model through multivariate logistic regression analysis. A combined DLCT parameter (C
resultsIn this study, there were 70 (26.52%) MSI-high (MSI-H) GC patients. Tumor location and CT_N staging were independent risk factors for MSI-H. In the validation set, the area under the curve (AUC) of the clinical model and DLCT model for predicting MSI status was 0.721 and 0.837, respectively. The combined model achieved a high prediction efficacy in the validation set, with AUC, sensitivity, and specificity of 0.879, 78.95%, and 75.4%, respectively. Survival analysis demonstrated that the combined model could stratify GC patients according to recurrence-free survival (p = 0.010).
conclusionThe combined model provides an efficient tool for predicting the MSI status of GC noninvasively and tumor recurrence risk stratification after surgery. CRITICAL RELEVANCE STATEMENT: MSI is an important molecular subtype in gastric cancer (GC). But MSI can only be evaluated using biopsy or postoperative tumor tissues. Our study developed a combined model based on DLCT which could effectively predict MSI preoperatively. Our result also showed that the combined model could stratify patients according to recurrence-free survival. It may be valuable for clinicians in choosing appropriate treatment strategies to avoid tumor recurrence and predicting clinical prognosis in GC. KEY POINTS: • Tumor location and CT_N staging were independent predictors for MSI-H in GC. • Quantitative DLCT parameters showed potential in predicting MSI status in GC. • The combined model integrating clinico-radiologic features and C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.